Deniz B Temel
About Deniz B Temel
Deniz B Temel is the Associate Scientific Director of Biologics Process and Analytical Integration at Bristol Myers Squibb in Massachusetts, United States, with over 8 years of experience in the biotech and biopharma industry.
Current Role at Bristol Myers Squibb
Deniz B Temel serves as the Associate Scientific Director Biologics Process and Analytical Integration at Bristol Myers Squibb in Massachusetts, United States. In this role, he leads a cross-functional team focusing on integrating analytical and process development strategies for biologics. His responsibilities include ensuring quality and transparency in processes and consistently exceeding company goals.
Previous Roles at Bristol Myers Squibb
Before his current role, Deniz B Temel held several positions at Bristol Myers Squibb. He was the Associate Director in Cell Therapy for five months in 2022 and served as the Analytical CMC Manager for three years from 2019 to 2022 in Devens, Massachusetts. Prior to that, he worked as a Senior Research Investigator from 2018 to 2019 in Cambridge, Massachusetts.
Work Experience at Amgen and Biogen
Deniz B Temel worked at Amgen as a Scientist from 2016 to 2018 in Thousand Oaks. He also held a position at Biogen as a Postdoctoral Scientist from 2013 to 2015 in Cambridge, Massachusetts, contributing to significant research projects in the biotech industry.
Academic Background and Research
Deniz B Temel holds a PhD in Physics from the City University of New York Graduate Center, where he studied from 2004 to 2011. He also attended Middle East Technical University, earning a BS/MS in Physics/Physics Education from 1999 to 2004. He has held various research positions, including at The Rockefeller University, Albert Einstein College of Medicine, and The City College of New York.
Industry Expertise and Leadership Skills
With over 8 years of experience in biotech and biopharma, Deniz B Temel is known for his expertise in biologics discovery and development. He is recognized for exceptional leadership in managing matrix teams and has been instrumental in the late-stage development of biologics. His peers regard him highly for his quality, transparent, and agile approach to work, often exceeding company expectations.